Box 1 Summary of pharmacodynamic properties at 150–600 mg/day
From: Role of trazodone in treatment of major depressive disorder: an update
• Antidepressant properties–antagonism of 5-HT2A and 5-HT2C receptors; inhibition of the serotonin transporter; 5HT1A partial agonism |
• Anxiolytic effects—5HT2c antagonism |
• Sleep improvement—5HT2a antagonism (H1 antagonism) and α1 receptor antagonism |
• Effects on agitation—α1 blockade and 5HT2a antagonism |
• Minimal anticholinergic effects |